Hypertension Diagnostics, Inc.
HDII · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 2.36 | -0.00 | 0.02 |
| FCF Yield | -54.74% | -0.42% | 162.19% | -220.06% |
| EV / EBITDA | -17.48 | -288.69 | 0.86 | 66.08 |
| Quality | ||||
| ROIC | 100.00% | 4.19% | 160.07% | 242.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 25.17% |
| Cash Conversion Ratio | 9.57 | 1.00 | 1.06 | 3.10 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 2.06% |
| Free Cash Flow Growth | -8,011.43% | -100.32% | 991.82% | -345.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -51.36 | 0.21 | 63.62 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 14.98 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 4.40 |